With the COVID-19 pandemic now ongoing for close to a year, people all over the world are
still waiting for a vaccine to become available. The initial focus of accelerated global …

Use of highly pure antigens to improve vaccine safety has led to reduced vaccine
immunogenicity and efficacy. This has led to the need to use adjuvants to improve vaccine …

Vaccines, including subunit, recombinant, and conjugate vaccines, require the use of an
immunostimulator/adjuvant for maximum efficacy. Adjuvants not only enhance the strength …

Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV)
epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to …

In Europe, many flaviviruses are endemic (West Nile, Usutu, tick-borne encephalitis viruses)
or occasionally imported (dengue, yellow fever viruses). Due to the temporal and …

SpikoGen® is a subunit recombinant spike protein vaccine combined with Advax‐CpG55.
2™ adjuvant. This COVID‐19 vaccine was shown to be safe, immunogenic and efficacious …

Usutu virus (USUV) is an African mosquito-borne flavivirus belonging to the Japanese
encephalitis virus serocomplex. USUV is closely related to Murray Valley encephalitis virus …

There is an ongoing need for new adjuvants to facilitate development of vaccines against
HIV, tuberculosis, malaria and cancer, amongst many others. Unfortunately, the most potent …

Respiratory syncytial virus (RSV) remains the most common cause of lower respiratory tract
infections in children worldwide. Development of a vaccine has been hindered by the risk of …

In the last three decades, several flaviviruses of concern that belong to different antigenic
groups have expanded geographically. This has resulted in the presence of often more than …